Urologic Cancers Clinical Trials

As a National Cancer Institute-designated comprehensive cancer center, City of Hope’s urology and urologic oncology program is uniquely positioned to provide personalized and comprehensive treatment plans, along with access to groundbreaking clinical trials.
 
For more than a decade, U.S. News & World Report has named City of Hope one of the top cancer hospitals in America, as well as named a high performing hospital in urology. Our world-class experts offer urology and urologic cancer patients, including those with complicated cases, access to a wide variety of trials, evaluating leading-edge treatments and innovative therapies.
 
To refer a patient to one of our clinical trials, please call 626-218-1133 or visit CityofHope.org/Clinical-Trials.
 

Advanced or Metastatic Urothelial Cancer

NCT04223856: Yung Lyou, M.D., Ph.D.,  is actively recruiting patients for a Phase 3 study on the benefits of a combination therapy to treat patients with untreated locally advanced or metastatic urothelial cancer. 
 
Clinical Trials Icon

Patient Enrollment Qualifications

  • 18 years of age or older
  • Histologically documented, unresectable locally advanced or metastatic urothelial carcinoma
  • Adequate hematologic and organ function
Learn More About This Promising Study  

Recurrent Locally Advanced or Metastatic Urothelial Cancer

NCT03237780: Yung Lyou, M.D., Ph.D.,  is actively recruiting patients for a Phase 2 study on the benefits of atezolizumab, with or without eribulin mesylate, in treating patients with urothelial cancer that has come back, or spread to nearby tissues and lymph nodes, or other places in the body.
 
 
Clinical Trials Icon
  • 18 years of age or older 
  • Histologically confirmed diagnosis of advanced/unresectable and/or metastatic transitional cell urothelial cancer of the renal pelvis, ureter, urinary bladder or urethra 
  • Life expectancy of ≥ 12 weeks
Learn More About This Promising Study  

Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

NCT04197986 Sumanta Pal, M.D.,  is actively recruiting patients for a Phase 3 trial studying the benefits of an oral targeted therapy for the adjuvant treatment of patients with invasive urothelial carcinoma with susceptible FGFR3 genetic alterations that is considered high risk for recurrence with surgery alone.
 
 
Clinical Trials Icon
  • 18 years of age or older
  • A histologically or cytologically confirmed, invasive urothelial carcinoma with susceptible FGFR3 alterations within 120 days following nephroureterectomy, distal ureterectomy or cystectomy
  • Patients must have no evidence of metastatic disease based on screening computed tomography or magnetic resonance imaging.
Learn More About This Promising Study